![Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors | Scientific Reports Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-023-36290-2/MediaObjects/41598_2023_36290_Fig1_HTML.png)
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors | Scientific Reports
![How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine - ScienceDirect How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497118638236-gr1.jpg)
How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine - ScienceDirect
Let's Flip: An Approach to Understand Median Follow-up by the Reverse Kaplan-Meier Estimator from a Statistical Programmer's
![Overall survival for suPAR levels above or below a 12 ng/mL cutoff.... | Download Scientific Diagram Overall survival for suPAR levels above or below a 12 ng/mL cutoff.... | Download Scientific Diagram](https://www.researchgate.net/publication/354290959/figure/fig4/AS:1063461807222804@1630560461526/Overall-survival-for-suPAR-levels-above-or-below-a-12ng-mL-cutoff-Median-follow-up-of.png)
Overall survival for suPAR levels above or below a 12 ng/mL cutoff.... | Download Scientific Diagram
![A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-09949-5/MediaObjects/41598_2022_9949_Fig1_HTML.png)
A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports
![Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum](https://discourse.datamethods.org/uploads/default/original/2X/7/75bb0160b856873819cdcefe4dc6072ed7ef267c.png)
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum
![Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/attachment/0b732d25-37b7-4d93-ad0b-8f60f96a958e/gr1.jpg)
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Let's Flip: An Approach to Understand Median Follow-up by the Reverse Kaplan-Meier Estimator from a Statistical Programmer's
![Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/attachment/2d946164-cd22-4ac0-b6fa-17e8eae70ab5/gr3_lrg.jpg)
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
![The overall survival did not reach median. The median progression free... | Download Scientific Diagram The overall survival did not reach median. The median progression free... | Download Scientific Diagram](https://www.researchgate.net/publication/347522939/figure/fig2/AS:971209084784641@1608565698438/The-overall-survival-did-not-reach-median-The-median-progression-free-survival-was-361.png)
The overall survival did not reach median. The median progression free... | Download Scientific Diagram
![Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-022-01845-z/MediaObjects/41416_2022_1845_Fig1_HTML.png)
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
![a Kaplan?Meier relapse-free survival (median follow-up time 42 months)... | Download Scientific Diagram a Kaplan?Meier relapse-free survival (median follow-up time 42 months)... | Download Scientific Diagram](https://www.researchgate.net/publication/301733304/figure/fig1/AS:479828383145984@1491411409128/a-KaplanMeier-relapse-free-survival-median-follow-up-time-42-months-of-all-cases-b.png)
a Kaplan?Meier relapse-free survival (median follow-up time 42 months)... | Download Scientific Diagram
![Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram](https://www.researchgate.net/publication/44901947/figure/fig1/AS:601654286118955@1520456968641/Survival-curves-A-Overall-survival-median-182-months-B-PS-of-zero-versus-one-or.png)